"10.1371_journal.pone.0059707","plos one","2013-03-20T00:00:00Z","Riley Bove; Elizabeth Secor; Brian C Healy; Alexander Musallam; Timothy Vaughan; Bonnie I Glanz; Emily Greeke; Howard L Weiner; Tanuja Chitnis; Paul Wicks; Philip L De Jager","Program in Translational NeuroPsychiatric Genomics, Department of Neurology, Institute for the Neurosciences, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America; Department of Neurology, Partners MS Center, Center for Neurologic Diseases, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America; Harvard Medical School, Boston, Massachusetts, United States of America; PatientsLikeMe, Inc., Cambridge, Massachusetts, United States of America; Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America","Intellectual contributions: BG TC. Conceived and designed the experiments: RB TV PW PLD. Performed the experiments: RB EG. Analyzed the data: ES BCH AM. Contributed reagents/materials/analysis tools: HW. Wrote the paper: RB PLD.","Dr. Vaughan and Dr. Wicks are employed by PatientsLikeMe, Inc. Dr.s Vaughan and Wicks hold stock options in the company. The PatientsLikeMe R&D team has received research support from Abbott, Accorda, Avanir, Biogen, Merck, Novartis, Sanofi, and UCB. PatientsLikeMe provided no financial support to the investigative team from Brigham & Women’s Hospital. Dr. Bove and MS Secor report no disclosures. Dr. Healy, Dr. Glanz and Ms. Greeke have received research support from Merck Serono. Dr. Weiner has served as a consultant for Biogen-Idec, EMD Serono, Genentech, GSK, Nasvax, Novartis, and Teva Neurosicences. Dr. Chitnis has served as a consultant for Biogen-Idec, Sanofi Aventis, Novartis, EMDSerono, and Teva Neurosciences, and has received grant support from Merck-Serono for unrelated activities. Dr. De Jager has received research support and speaker honoraria from Biogen-Idec and consultation fees from Teva. He has received research support from Biogen-IDEC, GlaxoSmithKline, and Sanofi-Aventis. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","03","Riley Bove","RB",11,TRUE,4,2,3,2,TRUE,FALSE,FALSE,0,NA,FALSE
